International Clinical Trial: The Study of JMT101 Combined With Irinotecan as a =3rd-Line Treatment in Metastatic Colorectal Cancer

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07134205) titled 'The Study of JMT101 Combined With Irinotecan as a =3rd-Line Treatment in Metastatic Colorectal Cancer' on Aug. 14.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Shanghai JMT-Bio Inc.

Condition: Metastatic Colorectal Cancer (mCRC)

Intervention: Drug: JMT101 Drug: Irinotecan

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: October 1, 2025

Target Sample Size: 252

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07134205

Published by HT D...